News

February 5, 2019

Round Table Pizza to Raise Funds for Leukemia & Lymphoma Society on National Pizza Day

News

Round Table Pizza will be celebrating National Pizza Day Feb. 9 by giving back to the Leukemia & Lymphoma Society (LLS) for every purchased pizza. Participating Round Table Pizza locations will donate ... Read more

February 4, 2019

2 Small RNA Molecules Suppress Lymphoma, Leukemia Development, Mouse Study Suggests

News

Two small non-coding RNA molecules — miR-146a and miR-146b — appear to protect against the development of blood cancers such as B-cell lymphoma and acute myeloid leukemia, a mouse study suggests. ... Read more

February 1, 2019February 1, 2019

Allogene’s Donor-derived CAR T-cell Therapy Cleared for Clinical Testing on Non-Hodgkin’s Lymphoma

News

Allogene Therapeutics and its partner Servier will soon launch a Phase 1/2 trial to assess the investigational cell therapy ALLO-501 in non-Hodgkin’s lymphoma patients who failed prior therapies, after the U.S. Food and ... Read more

January 31, 2019

FDA Approves Imbruvica-Gazyva Combo for First-line Treatment of CLL/SLL

News

The U.S. Food and Drug Administration has approved a combination of Imbruvica (ibrutinib) and Gazyva (obinutuzumab) for the initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). This is the ... Read more

January 30, 2019

Baseline and Interim PET Scans May Predict Long-Term Survival of PTCL Patients, Study Shows

News

Higher tumor volume at baseline and worse responses to chemotherapy after four cycles — measured with positron emission tomography (PET) scans — can predict poorer overall and event-free survival ... Read more

January 29, 2019

Gamida Cell, Be The Match BioTherapies Team Up on NiCord for Blood Cancers

News

A collaboration between cellular and immune therapeutics firm Gamida Cell and Be The Match BioTherapies is designed to widen the use of bone marrow transplants to treat blood cancers. The ... Read more

January 28, 2019

FDA Names Umbralisib ‘Breakthrough Therapy’ as Possible Treatment for Marginal Zone Lymphoma

News

The U.S. Food and Drug Administration (FDA) has designated umbralisib (TGR-1202), by TG Therapeutics, a breakthrough therapy as a possible treatment for adults with marginal zone lymphoma (MZL) who did not respond to at least ... Read more

January 25, 2019

2 Chemo Regimens Used Before Stem Cell Transplant Have Similar Effectiveness, Study Finds

News

A chemotherapy regimen called modified busulfan-cyclophosphamide (mBuCy) — which consists of busulfan, cyclophosphamide, semustine, and cytarabine — is as effective as standard chemotherapy in preparing lymphoma patients for a stem ... Read more

January 24, 2019

Imbruvica-Opdivo Combination Shows Promise in Richter’s Transformation

News

A combination of Imbruvica (ibrutinib) and Opdivo (nivolumab) reduced tumor burden in 65% of patients with Richter’s transformation — a kind of diffuse large B-cell lymphoma (DLBCL) with very poor prognosis, ... Read more

January 23, 2019

Genetic Profiling Identifies DLBCL Patients in Need of More Aggressive Treatment, Study Reports

News

Investigators in the U.K. have found a way to identify diffuse large B-cell lymphoma (DLBCL) patients who are less likely to respond to standard therapies and may require more ... Read more

Pin It on Pinterest